CITIUS ONCOLOGY

Company snapshot

Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is unde

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for CITIUS ONCOLOGY. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for CITIUS ONCOLOGY.

1. Jun 8, 2026 Clinical update

   Hydrocortisone acetate and lidocaine hydrochloride — Phase 2

2. Jun 5, 2026 Clinical update

   E7777 9 mcg/kg — Phase 3

3. May 23, 2026 Clinical update

   Monad 1 — Phase 2

View all clinical trial activity →

• What is CITIUS ONCOLOGY?

  Citius Oncology is a pharma organization headquartered in Cranford, USA. It trades on NYSE under ticker CTOR. Primary therapeutic focus areas include Hemorrhoids, Persistent or Recurrent Cutaneous T-Cell Lymphoma. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and

• Is CITIUS ONCOLOGY publicly traded?

  Yes. CITIUS ONCOLOGY is listed with ticker CTOR on NYSE per SEC EDGAR records linked on this profile.

• What drugs does CITIUS ONCOLOGY develop or market?

  We link 8 drug profile(s) where CITIUS ONCOLOGY is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/citius-oncology-inc#company-drugs.

• What are the latest developments for CITIUS ONCOLOGY?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does CITIUS ONCOLOGY focus on?

  CITIUS ONCOLOGY focuses on Hemorrhoids, Persistent or Recurrent Cutaneous T-Cell Lymphoma based on our analysis of their pipeline programs and drug development activities.